Dextran Or Derivative Patents (Class 514/59)
  • Patent number: 9925211
    Abstract: The invention features extracorporeal methods for the treatment of a subject having a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia. The invention also features devices used for the extracorporeal treatment of subjects have a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia.
    Type: Grant
    Filed: January 20, 2015
    Date of Patent: March 27, 2018
    Assignee: Beth Israel Deaconess Medical Center, Inc.
    Inventor: S. Ananth Karumanchi
  • Patent number: 9549946
    Abstract: The present invention provides pharmaceutical compositions in the form of relatively high molecular weight biocompatible polymers such as polyethylene glycol, optionally supplemented with a protective polymer such as dextran and/or essential pathogen nutrients such as L-glutamine. Also provided are methods for preventing or treating gut-derived sepsis attributable to intestinal pathogens such as Pseudomonas aeruginosa by administering high molecular weight polyethylene glycol as well as methods for monitoring the administration of high molecular weight polyethylene glycol, such as in methods of preventing, ameliorating or treating microbe-induced epithelial disorders, as exemplified by gut-derived sepsis. Frequently, gut-derived sepsis arises as a complication in mammals recovering from surgical intervention or suffering from a disease or disorder, providing indications of suitable animals to receive preventative treatment.
    Type: Grant
    Filed: November 9, 2015
    Date of Patent: January 24, 2017
    Assignee: THE UNIVERSITY OF CHICAGO
    Inventor: John C. Alverdy
  • Patent number: 9446066
    Abstract: Dextran sulfate is used in order to reduce pulmonary uptake of intravenously injected Dextran sulfate is capable of reducing the pulmonary uptake of the intravenously injected cells to the levels obtained for intraarterial injection of the cells but without the accompanying risks and side effects of using intraarterial cell injection. The dextran sulfate can therefore be used in a composition together with tumor infiltrating T-lymphocytes to treat metastatic cancer in a subject.
    Type: Grant
    Filed: July 8, 2011
    Date of Patent: September 20, 2016
    Assignee: TX MEDIC AB
    Inventors: Olle Korsgren, Bo Nilsson
  • Patent number: 9370202
    Abstract: A metal ion nanocluster having a formula of X(OH)aYbZcMd(H2O)e. X, Y, Z, M, a, b, c, d, and e are defined herein. The nanocluster has a particle size of 2 to 500 nm and a molecular weight of 3500 to 1000000 Dalton. Also disclosed are a composition containing the nanocluster and a method of preparing the nanocluster.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: June 21, 2016
    Assignee: LG Bionano, LLC
    Inventor: Chien-Chin Wu
  • Patent number: 9364499
    Abstract: A graft composition intended for transplantation into a patient comprises an injection solution comprising an isolated cell transplant and dextran sulfate, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: December 6, 2013
    Date of Patent: June 14, 2016
    Assignee: TX Medic AB
    Inventors: Bo Nilsson, Olle Korsgren
  • Patent number: 9051365
    Abstract: The present invention relates to antibodies or antigen binding fragments thereof that bind to complement Factor P and used thereof as well as combinations of anti-Factor P antibodies with antibodies or antigen binding fragments thereof that bind to complement component 5 (C5).
    Type: Grant
    Filed: December 17, 2012
    Date of Patent: June 9, 2015
    Assignee: Novartis AG
    Inventors: Leslie Ngozi Anuna Johnson, Ute Jaeger, Yong-In Kim, Christian Carsten Silvester Kunz, Igor Splawski, Michael Roguska, Joy Ghosh, Barbara Brannetti, Sha-Mei Liao, Michael Stefanidakis
  • Patent number: 9034843
    Abstract: The present invention provides an ophthalmic composition which stabilizes the tear film during wearing contact lens, prevents eye dryness, imparts a favorable sensation in using, is highly convenient with no risk of misuse and shows a high efficiency in the course from manufacturing to sales. More specifically, the present invention provides a wetting solution—eye drops for contact lenses comprising (A) one or more member(s) selected from the group consisting of a cellulose-based polymer, a vinyl-based polymer, polyethylene glycol and dextran; and (B) one or more member(s) selected from the group consisting of chondroitin sulfate, alginic acid and salts thereof; and (C) a nonionic surfactant.
    Type: Grant
    Filed: September 11, 2008
    Date of Patent: May 19, 2015
    Assignee: Rohto Pharmaceutical Co., Ltd.
    Inventors: Yasuko Matsumura, Kazuhiro Fukushima
  • Publication number: 20150132250
    Abstract: The invention features extracorporeal methods for the treatment of a subject having a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia. The invention also features devices used for the extracorporeal treatment of subjects have a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia.
    Type: Application
    Filed: January 20, 2015
    Publication date: May 14, 2015
    Inventor: S. Ananth KARUMANCHI
  • Publication number: 20150132360
    Abstract: Compositions and methods are provided for preparing an adhesion barrier in the form of a foldable or flexible biodegradable polymer matrix that effectively reduces, prevents or treats adhesions in a patient in need thereof. In one embodiment, the matrix comprises a first porous layer comprising collagen and a second porous layer comprising collagen and dextran, wherein the dextran is loaded in the second layer in an amount of from about 5% to about 90% by weight based on a total weight of the matrix. In some embodiments, the matrix prevents or reduces cell growth into the matrix so as to reduce or prevent adhesions. In some embodiments, the matrix is in a sheet or strip form that can be folded into a tube form.
    Type: Application
    Filed: November 8, 2013
    Publication date: May 14, 2015
    Applicant: Warsaw Orthopedic, Inc.
    Inventor: Scott M. Vickers
  • Patent number: 9023831
    Abstract: A method of inhibiting the adverse effects of complement pathway, activation products in a subject comprising administering to the subject an amount of Dextran Sulfate effective to inhibit formation of alternative complement pathway activation product.
    Type: Grant
    Filed: April 24, 2008
    Date of Patent: May 5, 2015
    Assignee: Novelmed Therapeutics, Inc.
    Inventor: Rekha Bansal
  • Patent number: 9018190
    Abstract: The invention relates to an oligodextran, chosen from dextrans whose average degree of polymerization is less than 10, modified by at least one substituent of general formula I: —R1-[[AA]-[R2]n]m??formula I It also relates to a pharmaceutical composition characterized in that it comprises an oligosaccharide according to the invention and an active ingredient is chosen from the group consisting of proteins, glycoproteins, peptides and non-peptide therapeutic molecules.
    Type: Grant
    Filed: May 10, 2012
    Date of Patent: April 28, 2015
    Assignee: ADOCIA
    Inventors: Richard Charvet, Remi Soula, Olivier Soula
  • Publication number: 20150105346
    Abstract: A tissue adhesive formed by reacting an aminodextran containing primary amine groups with an oxidized dextran containing aldehyde groups is described. The dextran-based polymer tissue adhesive is particularly useful in medical applications where low swell and slow degradation are needed, for example sealing the dura, ophthalmic procedures, tissue repair, antiadhesive applications, drug delivery, and as a plug to seal a fistula or the punctum.
    Type: Application
    Filed: August 21, 2014
    Publication date: April 16, 2015
    Applicant: Actamax Surgical Materials, LLC
    Inventor: Helen S.M Lu
  • Publication number: 20150098970
    Abstract: Biofunctional films and methods of use thereof for the prevention of post-operative adhesions are disclosed.
    Type: Application
    Filed: December 12, 2014
    Publication date: April 9, 2015
    Inventors: Noshir Langrana, Devendra Verma, Michelle Previtera
  • Patent number: 8987230
    Abstract: The present invention provides a composition comprising a hyaluronic acid derivative having a crosslinking group(s) and a hydrophilic polysaccharide derivative having a hydrophobic group(s), wherein the hyaluronic acid derivative having a crosslinking group(s) is prepared by crosslinkage formation reaction in hyaluronic acid or a derivative thereof having a crosslinkable group(s) in the presence of the hydrophilic polysaccharide derivative wherein the hydrophilic polysaccharide derivative may have a crosslinkable group(s).
    Type: Grant
    Filed: April 30, 2008
    Date of Patent: March 24, 2015
    Assignees: National University Corporation Tokyo Medical and Dental University, Chugai Seiyaku Kabushiki Kaisha
    Inventors: Kazunari Akiyoshi, Nobuyuki Morimoto, Tai Hirakura, Tsuyoshi Shimoboji
  • Patent number: 8969322
    Abstract: The invention features extracorporeal methods for the treatment of a subject having a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia. The invention also features devices used for the extracorporeal treatment of subjects have a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia.
    Type: Grant
    Filed: May 13, 2011
    Date of Patent: March 3, 2015
    Assignee: Beth Israel Deconess Medical Center, Inc.
    Inventor: S. Ananth Karumanchi
  • Patent number: 8969323
    Abstract: The present invention relates to priming solutions used during cardiopulmonary bypass procedures. In particular, the present invention relates to a cardiopulmonary bypass priming solution comprising a balanced salt solution and a combination of oncotic and non-oncotic dextran molecules. The present invention also relates to the use of the priming solution in a cardiopulmonary bypass method, a method of maintaining oncotic pressure in a patient during a cardiopulmonary bypass procedure, and a combination of cardiopulmonary bypass priming solution and cardiopulmonary bypass apparatus.
    Type: Grant
    Filed: November 7, 2011
    Date of Patent: March 3, 2015
    Assignee: XVIVO Perfusion AB
    Inventor: Stig Steen
  • Publication number: 20150057685
    Abstract: Laminate or knitted medical devices and methods using such devices to support soft tissues and/or to reduce formation of post-operative adhesions. The medical devices can comprise a layer of a knitted silk mesh to which has been fused a water soluble or insoluble silk film or silk sponge, and/or a layer of a knitted silk mesh which was co-knitted with one, two or three layers of silk or non-silk fabric.
    Type: Application
    Filed: August 13, 2014
    Publication date: February 26, 2015
    Inventors: Monica A. Serban, Susan E. Burke, William A. Daunch, Vinit Patel, Bryan W. Jones
  • Publication number: 20150057244
    Abstract: This invention provides a method of preventing or treating a dermatologic condition including, inter alia, psoriasis, contact dermatitis, and atopic dermatitis, in a subject, the method includes the step of administering to said subject a compound comprising a lipid or phospholipid moiety bound to a physiologically acceptable monomer, dimer, oligomer, or polymer, and/or a pharmaceutically acceptable salt or a pharmaceutical product thereof, in an amount effective to treat the subject suffering from a dermatologic condition.
    Type: Application
    Filed: November 5, 2014
    Publication date: February 26, 2015
    Inventors: SAUL YEDGAR, Miron Krimsky, Arie Ingber
  • Publication number: 20150050366
    Abstract: Some embodiments of a system or method for applying a barrier composition to a targeted skin surface can be used to as a preventative measure to reduce the likelihood of transmission of microbial entities from an external source (e.g., a floor surface or another surface) to the targeted skin surface.
    Type: Application
    Filed: August 13, 2013
    Publication date: February 19, 2015
    Inventors: Aner Vlodaver, Benhoor Soumekh, Smarajit Mitra, Sumita B. Mitra
  • Patent number: 8951989
    Abstract: A hydrogel tissue adhesive having decreased degradation time is described. The hydrogel tissue adhesive is formed by reacting an oxidized polysaccharide with a water-dispersible, multi-arm polyether amine in the presence of an oligomer additive, which promotes the degradation of the hydrogel. The hydrogel may be useful as a tissue adhesive or sealant for medical applications, such as a hemostat sealant or to prevent undesired tissue-to-tissue adhesions resulting from trauma or surgery.
    Type: Grant
    Filed: April 9, 2010
    Date of Patent: February 10, 2015
    Assignee: Actamax Surgical Materials, LLC
    Inventor: Mark E. Wagman
  • Patent number: 8926947
    Abstract: Iron oxide complexes, pharmacological compositions and unit dosage thereof, and methods for their administration, of the type employing an iron oxide complex with a polyol, are disclosed. The pharmacological compositions employ a polysaccharide iron oxide complex, wherein the polysaccharide is a modified polyol such as a carboxyalkylated reduced dextran. The complex is stable to terminal sterilization by autoclaving. The compositions are suitable for parenteral administration to a subject for the treatment of iron deficiencies or as MRI contrast agent. The complex is substantially immunosilent, provide minimal anaphylaxis and undergo minimal dissolution in vivo. The pharmacological compositions of the complex contain minimal free iron which can be quantified by a variety of methods.
    Type: Grant
    Filed: June 11, 2014
    Date of Patent: January 6, 2015
    Assignee: AMAG Pharmaceuticals, Inc.
    Inventors: Ernest V. Groman, Kenneth G. Paul, Timothy B. Frigo, Howard Bengele, Jerome M. Lewis
  • Publication number: 20150004140
    Abstract: Compositions for improving the health of a subject comprise alpha-(1,2)-branched alpha-(1,6) oligodextrans, preferably with an average molecular weight between about 10 kDa and 70 kDa, between about 10% and 50% alpha-(1,2)-osidic side chains, and having at least partial indigestibility in the subject. Methods for improving the health of a subject comprise administering the composition to a subject in an amount effective to improve gut health, or to prevent or treat a gastrointestinal disorder, a cholesterol-related disorder, diabetes, or obesity. Methods for making oligodextrans having controlled size and controlled degree of branching comprise providing alpha-(1,6) oligodextrans having an average molecular weight between 0.5 and 100 kDa and introducing at least 10% alpha-(1,2)-osidic side chains onto the alpha-(1,6) oligodextrans.
    Type: Application
    Filed: July 11, 2014
    Publication date: January 1, 2015
    Inventors: Thierry NAEYE, Alexandra Eilnerhand, Michel Lopez, Susan M. Potter, Magali Remaud-Siméon, Pierre Frédéric Emmanuel Monsan
  • Patent number: 8921337
    Abstract: The present invention generally relates to suspension compositions having a carboxyvinyl polymer such as a carbomer, a galactomannan such as guar, and a borate compound. A sparingly soluble particulate compound such as nepafenac is also included in the compositions. The sparingly soluble particulate compound has a small particle size to enhance bioavailability of the compound.
    Type: Grant
    Filed: December 1, 2010
    Date of Patent: December 30, 2014
    Assignee: Alcon Research, Ltd.
    Inventors: Masood A. Chowhan, Malay Ghosh, Bahram Asgharian, Wesley Wehsin Han
  • Patent number: 8906882
    Abstract: Provided herein are methods of treating, suppressing, inhibiting, or preventing allergic rhinitis in a subject comprising the step of administering to a subject a compound comprising a lipid or phospholipid moiety bond to a physiologically acceptable monomer, dimer, oligomer, or polymer, and/or a pharmaceutically acceptable salt or a pharmaceutical product thereof.
    Type: Grant
    Filed: December 12, 2011
    Date of Patent: December 9, 2014
    Assignee: Yissum Research Development Company of The Hebrew University of Jerusalem
    Inventor: Saul Yedgar
  • Patent number: 8906884
    Abstract: The present invention refers to use of dextran sulfate, or a pharmaceutically acceptable derivate thereof, for manufacturing of a medicament for treatment of Instant Blood-Mediated Inflammatory Reaction (IBMIR). In addition, the invention refers to the use of dextran sulfate, or a pharmaceutically acceptable derivate thereof, for manufacturing of a medicament for treatment of morphological disruption of cell transplants and graft-rejection of cell transplants caused by IBMIR. The invention may be applied to patients suffering from type I diabetes, in which porcine islets of Langerhans are transplanted in their portal vein. Administration of dextran sulfate according to the invention inhibits and prevents rejection and destruction of the transplanted islets and makes normoglycemia in the patients possible.
    Type: Grant
    Filed: January 11, 2010
    Date of Patent: December 9, 2014
    Assignee: TX Medic AB
    Inventors: Bo Nilsson, Olle Korsgren
  • Patent number: 8901104
    Abstract: A method of inhibiting Instant Blood-Mediated Inflammatory Reaction (IBMIR) in a patient, comprises administering a therapeutically effective amount of dextran sulfate, or a pharmaceutically acceptable salt thereof. A method of inhibiting morphological disruption of a transplanted cell transplant in a patient comprises administering a therapeutically effective amount of dextran sulfate, or a pharmaceutically acceptable salt thereof, to a patient. The dextran sulfate, or said pharmaceutically acceptable salt thereof, has an average molecular weight of less than 20,000 Da and an average sulphur content in a range of 10 to 25%, and the inhibition comprises administering said therapeutically effective amount of said dextran sulfate, or said pharmaceutically acceptable salt thereof, resulting in a concentration of said dextran sulfate, or said pharmaceutically acceptable salt thereof, in the blood of said patient of less than 5 mg/ml.
    Type: Grant
    Filed: December 6, 2013
    Date of Patent: December 2, 2014
    Assignee: TX Medic AB
    Inventors: Bo Nilsson, Olle Korsgren
  • Patent number: 8895612
    Abstract: The present invention generally relates to treatment of iron-related conditions with iron carbohydrate complexes. One aspect of the invention is a method of treatment of iron-related conditions with a single unit dosage of at least about 0.6 grams of elemental iron via an iron carbohydrate complex. The method generally employs iron carbohydrate complexes with nearly neutral pH, physiological osmolarity, and stable and non-immunogenic carbohydrate components so as to rapidly administer high single unit doses of iron intravenously to patients in need thereof.
    Type: Grant
    Filed: December 9, 2013
    Date of Patent: November 25, 2014
    Assignee: Luitpold Pharmaceuticals, Inc.
    Inventors: Mary Jane Helenek, Marc L. Tokars, Richard P. Lawrence
  • Publication number: 20140343013
    Abstract: Compositions comprising a glycosaminoglycan (e.g., a hyaluronan, hyaluronic acid, hyaluronate, sodium hyaluronate, dermatan sulfate, karatan sulfate, chondroitin 6-sulfate, heparin, etc.) in combination with at least one component selected from; i) polyglycols (e.g., polyethylene glycol), ii) long chain hydroxy polyanionic polysaccharides (e.g., dextran, sodium alginate, alginic acid, propylene glycol alginate, carboxymethyl cellulose and carboxyethyl cellulose, hydroxyl ethyl starch, hydroxyl propyl methyl cellulose, hydroxy propyl ethyl cellulose, hydroxy propyl cellulose, methyl cellulose, polylysine, polyhistidine, polyhydroxy proline, poly ornithine, polyvinyl pyrolidone, polyvinyl alcohol, chitosan, etc.) and iii) long chain Nitrogen containing polymers (e.g., Polylysine, Polyvinylpyrrolidone, and polyvinyl alcohol). The invention also includes methods for using such compositions (e.g., as substance delivery materials, tissue fillers or bulking agents, as moistening or hydrating agents, etc.
    Type: Application
    Filed: April 14, 2014
    Publication date: November 20, 2014
    Applicant: S.K. Pharmaceuticals
    Inventors: Hampar Karageozian, John Park
  • Patent number: 8883715
    Abstract: A process for treating fibroses including administering a therapeutically effective amount of a pharmaceutical composition which includes at least one biocompatible polymer of the following general formula (I): AaXxYy wherein: A represents a monomer selected from the group consisting of a sugar or —(O—CH2—CH2—CO)—, X represents a carboxyl group bonded to monomer A, Y represents a sulfate or sulfonate group bonded to monomer A a represents the number of monomers A such that the mass of the polymers of formula (I) is greater than approximately 5,000 da, x represents a substitution rate of the monomers A by the groups X, which is between approximately 20 and 150%, and y represents a substitution rate of the monomers A by the groups Y, which is between approximately 30 and 150%.
    Type: Grant
    Filed: April 12, 2013
    Date of Patent: November 11, 2014
    Inventors: Denis Barritault, Jean-Pierre Caruelle
  • Publication number: 20140315855
    Abstract: The invention relates to the cosmetic use of a sulfated polysaccharide chosen from: dextran sulfate and sulfated polysaccharides derived from the red alga Porphyridium sp, as active agent for preventing and/or treating dandruff of the scalp.
    Type: Application
    Filed: December 14, 2012
    Publication date: October 23, 2014
    Inventors: Anne Potter, Sebastien Thibaut, Christele Ribaut
  • Publication number: 20140308351
    Abstract: Methods are described for producing non-immunogenic nanoparticles from protein sources by controlling the pH in a nanoprecipitation process. The nanoparticles that are produced by the disclosed methods range in diameter size from about 100 ran to about 400 nm, with a preferred diameter size of from approximately 100 nm to approximately 300 nm, thereby rendering them non-immunogenic. The invention further discloses methods for producing nanoconjugates that are suitable for a variety of therapeutic, diagnostic and other uses.
    Type: Application
    Filed: March 10, 2014
    Publication date: October 16, 2014
    Applicant: South Dakota State University
    Inventors: Omathanu P. Perumal, Satheesh K. Podaralla, Radhey S Kaushik
  • Patent number: 8858917
    Abstract: Formulations have been developed for pulmonary delivery to treat or reduce the infectivity of diseases such as vital infections, especially tuberculosis, SARS, influenza and respiratory synticial virus in humans and hoof and mouth disease in animals. Formulations for pulmonary administration include a material that significantly alters physical properties such as surface tension and surface elasticity of lung mucus lining fluid, which may be a surfactant and, optionally, a carrier. The formulation may be administered as a powder where the particles consist basically of the material altering surface tension. The carrier may be a solution, such as an alcohol, although an aqueous solution may be utilized, or a material mixed with the material altering surface tension to form particles.
    Type: Grant
    Filed: January 9, 2009
    Date of Patent: October 14, 2014
    Assignee: President and Fellows of Harvard College
    Inventors: David A. Edwards, Howard A. Stone
  • Patent number: 8859705
    Abstract: A hydrogel tissue adhesive having decreased gelation time and decreased degradation time is described. The hydrogel tissue adhesive is formed by reacting an oxidized polysaccharide containing aldehyde groups with a water-dispersible, multi-arm amine in the presence of a thiol additive. The thiol additive accelerates the process to form the hydrogel and accelerates the degradation of the hydrogel formed. The hydrogel may be useful as a tissue adhesive or sealant for medical applications, such as a hemostat sealant or to prevent undesired tissue-to-tissue adhesions resulting from trauma or surgery.
    Type: Grant
    Filed: November 19, 2012
    Date of Patent: October 14, 2014
    Assignee: Actamax Surgical Materials LLC
    Inventors: Helen S. M. Lu, Cara L. Blankenbicker
  • Publication number: 20140301972
    Abstract: The invention relates to a biocompatible polymer having general formula (I) AaXxYy, wherein: A denotes a monomer; X denotes an RCOOR? group; Y denotes an O or N-sulphonate group which is fixed to A and which has either formula —ROS03R? or —RNS03R? in which R denotes an optionally branched and/or unsaturated aliphatic hydrocarbon chain which can contain one or more aromatic rings and R? denotes a hydrogen atom or a cation; a denotes the number of monomers; x denotes the rate of substitution of the A monomers by the X groups; and y denotes the rate of substitution of the A monomers by the Y groups. More specifically, the invention relates to the use of said biocompatible polymers for the preparation of a pharmaceutical, dermatological or cosmetic composition or a medical device, which are intended to prevent, relieve and/or treat discomfort, distress, itches, irritations and/or pain and/or to protect tissues against same.
    Type: Application
    Filed: June 18, 2014
    Publication date: October 9, 2014
    Inventors: Denis BARRITAULT, Veronique Barbier-Chassefiere
  • Patent number: 8815301
    Abstract: The invention relates to an iron oligosaccharide compound with improved stability comprising a hydrogenated oligosaccharide in stable association with ferric oxyhydroxide, the content of dimer saccharide in said hydrogenated oligosaccharide being 2.9% by weight or less, based on the total weight of the hydrogenated oligosaccharide. In further aspects is provided a process for preparing said compound as well as the use of said compound for preparation of a composition for treatment of iron deficiency anaemia.
    Type: Grant
    Filed: March 25, 2009
    Date of Patent: August 26, 2014
    Assignee: Pharmacosmos Holding A/S
    Inventor: Hans Andreasen
  • Patent number: 8796242
    Abstract: A hydrogel tissue adhesive formed by reacting an aldehyde-functionalized polysaccharide containing pendant aldehyde groups with a water-dispersible, multi-arm amine is described. The hydrogel may be useful as a tissue adhesive or sealant for medical applications that require a more rapid degradation time, such as the prevention of undesired tissue-to tissue adhesions resulting from trauma or surgery.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: August 5, 2014
    Assignee: Actamax Surgical Materials, LLC
    Inventors: Helen S.M. Lu, Steven W. Shuey
  • Publication number: 20140212373
    Abstract: A multi-vinylsulfone containing molecule is described herein. The multi-vinylsulfone containing molecule can be formed by dissolving a water soluble polymer containing a hydroxyl group in an aqueous solution to form a polymer solution; adding a molecule containing two vinylsulfone groups to the polymer solution; and forming a modified polymer by controlling a number of the vinylsulfone groups that are added to the polymer. A hydrogel is also described herein that can include the multi-vinylsulfone containing molecule and a multi-thiol containing molecule. The hydrogel can be formed from an aqueous solution that includes the multi-vinylsulfone containing molecule and the multi-thiol containing molecule by undergoing gelatation upon delivery to a site in the body. Also described is a drug delivery system that employs the hydrogel.
    Type: Application
    Filed: June 15, 2012
    Publication date: July 31, 2014
    Applicant: THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY
    Inventors: Ying Chau, Yu Yu
  • Publication number: 20140212457
    Abstract: The present invention relates to compounds which are capable of exerting an inhibitory effect on the Na+ glucose cotransporter SGLT in order to hinder glucose and galactose absorption, as well as on lipase thus reducing dietary triglyceride metabolism, for use in the treatment of conditions which benefit therefrom (diabetes. Metabolic Syndrome, obesity, prevention of weight gain or aiding weight loss). These compounds comprise a non-absorbable, non-digestible polymer having a glucopyranosyl or galactopyranosyl or equivalent moiety stably and covalently linked thereto, said glucopyranosyl or galactopyranosyl moiety being able to occupy the glucose-binding pocket of a SGLT transporter.
    Type: Application
    Filed: August 12, 2013
    Publication date: July 31, 2014
    Inventor: Abdalla Rifai
  • Publication number: 20140206644
    Abstract: The present invention provides compositions and methods to inhibit fibrosis and scarring associated with surgery. The present invention relates to the discovery that a synthetic anionic polymer consisting of dextran-sulfate (anionic carbohydrate) conjugated to Tirofiban (an anti-platelet agent which prevents platelet activation and aggregation) can effectively inhibit adhesions that form during surgery. This application is a continuation in part to U.S. patent application Ser. No. 13/202,006. The novel biocompatible conjugate compound of the original application can effectively inhibit fibrosis, scar formation, and surgical adhesions. The invention is predicated on the discovery that the conjugate compound effectively inhibits the invasion of cells which is associated with detrimental healing processes without affecting platelet populations. Use of any of several different anionic components with any of several different anti-platelet agents results in many different specific embodiments of the invention.
    Type: Application
    Filed: March 24, 2014
    Publication date: July 24, 2014
    Inventor: Rekha Bansal
  • Patent number: 8778326
    Abstract: A hydrogel tissue adhesive formed by reacting an aldehyde-functionalized polysaccharide containing pendant aldehyde groups with a water-dispersible, multi-arm amine is described. The hydrogel may be useful as a tissue adhesive or sealant for medical applications that require a more rapid degradation time, such as the prevention of undesired tissue-to tissue adhesions resulting from trauma or surgery.
    Type: Grant
    Filed: June 30, 2010
    Date of Patent: July 15, 2014
    Assignee: Actamax Surgical Materials, LLC
    Inventors: Helen S. M. Lu, Steven W. Shuey
  • Patent number: 8759320
    Abstract: Process for the preparation of trivalent iron complexes with mono-, di- and polysaccharide sugars, consisting of the activation of the sugar by oxidation with nascent bromine generated in situ by reaction between an alkaline or alkaline earth bromine and an alkaline hypochlorite, the complexation of the activated sugar in solution with a ferric salt dissolved in an aqueous solution, the purification of the resulting solution through ultrafiltration and finally the stabilization of the trivalent iron-sugar complex by heating at a temperature between 60° C. and 100° C. for a period between 1 and 4 hours at a pH between 9.0 and 11.0.
    Type: Grant
    Filed: March 14, 2006
    Date of Patent: June 24, 2014
    Assignee: Biofer S.p.A.
    Inventors: Stefania Sacchi, Mauro Montorsi, Egidio Marchi
  • Publication number: 20140162974
    Abstract: Compositions and methods for decreasing phosphorus, decreasing cFGF23, or increasing iFGF23 in a subject. Such compositions and methods can be useful for treatment of conditions, disorders, or diseases associated with phosphorus or FGF23 disregulation.
    Type: Application
    Filed: March 5, 2013
    Publication date: June 12, 2014
    Applicant: LUITPOLD PHARMACEUTICALS, INC.
    Inventors: David B Bregman, Marc L Tokars
  • Patent number: 8735570
    Abstract: Cationic dextran polymer derivatives including an ester-linked amine-containing substituent and an alkyl ester substituent and methods for making such dextran polymer derivatives are disclosed.
    Type: Grant
    Filed: May 14, 2012
    Date of Patent: May 27, 2014
    Assignee: Bend Research, Inc.
    Inventors: Warren K. Miller, Michael M. Morgen, Corey J. Bloom
  • Publication number: 20140142063
    Abstract: A hydrogel tissue adhesive having decreased gelation time and decreased degradation time is described. The hydrogel tissue adhesive is formed by reacting an oxidized polysaccharide containing aldehyde groups with a water-dispersible, multi-arm amine in the presence of a thiol additive. The thiol additive accelerates the process to form the hydrogel and accelerates the degradation of the hydrogel formed. The hydrogel may be useful as a tissue adhesive or sealant for medical applications, such as a hemostat sealant or to prevent undesired tissue-to-tissue adhesions resulting from trauma or surgery.
    Type: Application
    Filed: November 19, 2012
    Publication date: May 22, 2014
    Applicant: Actamax Surgical Materials, LLC
    Inventors: Helen S.M. Lu, Cara L. Blankenbicker
  • Publication number: 20140135286
    Abstract: Compositions and methods are provided for preparing an adhesion barrier that effectively reduce, prevent or treat adhesions in a patient in need thereof. In one embodiment, a matrix is provided comprising a biodegradable polymer and dextran loaded in the matrix in an amount of from about 5% to about 90% by weight based on a total weight of the matrix. The matrix is configured to release from about 30% to about 90% of the dextran loaded in the matrix within 24 to 48 hours.
    Type: Application
    Filed: March 12, 2013
    Publication date: May 15, 2014
    Applicant: Warsaw Orthopedic, Inc.
    Inventors: William F. McKay, Ping Li
  • Publication number: 20140135285
    Abstract: Methods and compositions are provided for reducing, treating or preventing adhesions in a patient in need of such treatment. In one embodiment, an implantable device is provided for reducing or preventing adhesion formation at a post-operative tissue site in a patient, the implantable device including a biodegradable porous matrix comprising dextran, wherein the implantable device is capable of releasing the dextran over at least 2 days.
    Type: Application
    Filed: November 12, 2012
    Publication date: May 15, 2014
    Applicant: Warsaw Orthopedic, Inc.
    Inventor: William F. McKay
  • Publication number: 20140134226
    Abstract: Compositions and methods are provided for a matrix that inhibits bone growth in a patient in need thereof. In one embodiment, a method of inhibiting bone growth is provided, the method comprising: implanting a matrix at a target tissue site, the matrix comprising a biodegradable polymer and dextran loaded in the matrix in an amount of from about 5% to about 95% by weight based on a total weight of the matrix.
    Type: Application
    Filed: March 12, 2013
    Publication date: May 15, 2014
    Applicant: Warsaw Orthopedic, Inc.
    Inventors: William F. McKay, Ping Li
  • Patent number: 8715701
    Abstract: Protein preparations containing biologically active compounds and the application of the protein preparations obtained, particularly as a component of medicinal and cosmetic preparations as protective substances or in the regeneration of cells and tissues of the human organism, and which can comprise a component of culture media for dermal or hepatic tissues, or for stem cells destined for use in the regeneration of cells and tissues in the human organism.
    Type: Grant
    Filed: November 20, 2007
    Date of Patent: May 6, 2014
    Assignee: Instytut Medycyny Doswiadczalnej I Klinicznej
    Inventors: Andrzej Lipkowski, Anna Grabowska, Katarzyna Kurzepa, Aleksandra Szczucinska
  • Publication number: 20140100190
    Abstract: This invention provides for the use of compounds represented by the structure of the general formula (A): wherein L is a lipid or a phospholipid, Z is either nothing, ethanolamine, serine, inositol, choline, or glycerol, Y is either nothing or a spacer group ranging in length from 2 to 30 atoms, X is a physiologically acceptable monomer, dimer, oligomer, or polymer, wherein X is a glycosaminoglycan; and n is a number from 1 to 1000, wherein any bond between L, Z, Y and X is either an amide or an esteric bond in treating a subject suffering from cystic fibrosis, reducing or delaying the mortality of a subject suffering from cystic fibrosis or ameliorating symptoms associated with cystic fibrosis.
    Type: Application
    Filed: November 4, 2013
    Publication date: April 10, 2014
    Applicants: Columbia University, Yissum Research Development Company of The Hebrew University of Jerusalem LTD
    Inventors: Saul Yedgar, Alice Prince, Yuval Cohen
  • Patent number: 8691286
    Abstract: A composition for dissolving or reducing the viscosity of sputum on a surface of a device includes an effective amount of glycerol and an effective amount of dextran sulfate in a saline solution. The effective amount of glycerol is between about 30-50% and the effective amount of dextran sulfate is between about 10-30%. The composition may further include an antimicrobial agent.
    Type: Grant
    Filed: January 26, 2010
    Date of Patent: April 8, 2014
    Assignee: Teleflex Medical Incorporated
    Inventors: Nisha Gupta, Erin Peters, Joel Rosenblatt